Results 1 to 10 of about 4,722 (149)

Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy. [PDF]

Adv Sci (Weinh)
This work develops a metabolic sharing strategy that employs cytidine monophosphate (CMP) to competitively reprogram floxuridine (FUDR) pyrimidine metabolism in colorectal tumor cells. Elevated intracellular FdUMP induces nucleotide imbalance, drives mitochondrial DNA release and cGAS‐STING innate immune cascade activation, and potentiates robust ...
Wang C, Zhao C, Yao Y, Zou Z, Shi A, Feng Z, Yang M, Yu Y, Liu Y, Rui X, Wu J.   +10 more
europepmc   +2 more sources

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity. [PDF]

Int J Cancer
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Gambron M, Peruzzi E, Perfler S, Montico M, Cecchin R, De Mattia E, Spina M, Lisanti C, Corsetti S, Foltran L, Puglisi F, Roncato R, Cecchin E.   +12 more
europepmc   +2 more sources

Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real‐World Practice: A Retrospective Cohort Study [PDF]

Cancer Medicine
Introduction The European Summary of Product Characteristics (SmPC) for 5‐FU warns of significant granulocyte decline when combined with thiazides, cyclophosphamide, or methotrexate, based on a 1981 cohort of 14 patients.
Gerard Ronda‐Roca, José Porcel‐Maleno, Mónica Lobo‐Palomar, Gustavo Centeno‐Soto, Ana Ruiz‐Casado, Belén Ruiz‐Antorán   +5 more
doaj   +2 more sources

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger [PDF]

Frontiers in Pharmacology
IntroductionFluoropyrimidines (FP) are the mainstay of colorectal cancer (CRC) treatment, but can cause severe toxicity in up to 40% of patients. Variants in the DPYD gene are associated with these adverse events.
Rocío Rosas-Alonso, Rocío Rosas-Alonso, Nuria Rodríguez Salas, Nuria Rodríguez Salas, Pablo Perez Wert, Angela Hoyo, Susana Martin-López, Daniel Martínez-Pérez, Iciar Ruiz-Gutiérrez, Diego Jiménez-Bou, Jesús Peña, Pedro Arias, Ana Custodio, Ana Custodio, Itsaso Losantos-García, Alberto M. Borobia, Alberto M. Borobia, Jaime Feliu, Jaime Feliu, Jaime Feliu, Ismael Ghanem, Ismael Ghanem   +21 more
doaj   +2 more sources

Balance of care activity after EMA recommendation for DPYD gene testing in Galicia [PDF]

Frontiers in Pharmacology
IntroductionSince April 2020, pretherapeutic screening for accessing the deficiency of the DPD enzyme by genotyping the dihydropyrimidine dehydrogenase gene (DPYD) is required by the European Medicine Agency (EMA) prior to the administration of ...
Almudena Gil-Rodríguez, Almudena Gil-Rodríguez, Sheila Recarey-Rama, Sheila Recarey-Rama, Ana Rodríguez-Viyuela, Ana Rodríguez-Viyuela, Francisco Barros, Francisco Barros, Angel Carracedo, Angel Carracedo, Angel Carracedo, Angel Carracedo, Olalla Maroñas, Olalla Maroñas, Olalla Maroñas, Olalla Maroñas   +15 more
doaj   +2 more sources

Identification of TgENT1 as the TgUUT1 Uracil/Uridine Transporter of Toxoplasma gondii [PDF]

Pathogens
The protozoan pathogen Toxoplasma gondii is responsible for toxoplasmosis, a disease that can be deadly in immunocompromised patients and the developing fetus during pregnancy. Current treatments are widely considered to be suboptimal.
Hamza A. A. Elati, Mariana Ferreira Silva, Lilach Sheiner, Harry P. de Koning   +3 more
doaj   +2 more sources

Trifluridine- and tipiracil-induced DPD inhibition mimicking DPD deficiency: a case report [PDF]

Frontiers in Oncology
Fluoropyrimidines, including 5-fluorouracil (5-FU) and its derivatives, remain the standard first-line treatment for metastatic colorectal cancer (mCRC).
Antonin Schmitt, Baptiste Bouillet, Bernard Royer, Bernard Royer, François Ghinringhelli   +4 more
doaj   +2 more sources

Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis

South Asian Journal of Cancer, 2022
Shikha Verma Background Systemic fluoropyrimidines, both oral and intravenous, are an integral part of colorectal cancer (CRC) management. They can be administered either with curative or palliative intent.
Satya Pal Kataria, Mukesh Nagar, Shikha Verma, Vinay Purohit   +3 more
doaj   +1 more source

Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation

Pharmaceuticals, 2022
Hand-Foot syndrome (HFS) and diarrhoea are dose-limiting Adverse Drug Reactions (ADRs) of capecitabine-based chemotherapy. Four polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene, encoding the DPD enzyme responsible for the metabolism of ...
Berenice Stefanelli, Carmine Sellitto, Emanuela De Bellis, Martina Torsiello, Nicola Bertini, Angelo Maria Pezzullo, Graziamaria Corbi, Francesco Sabbatino, Stefano Pepe, Angela Tesse, Valeria Conti, Amelia Filippelli   +11 more
doaj   +1 more source

Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis

World Journal of Surgical Oncology, 2021
Background To evaluate whether the addition of taxanes to platinum and fluoropyrimidines in adjuvant chemotherapy would result in longer survival than platinum plus fluoropyrimidines in gastric cancer patients who received D2 gastrectomy. Methods Data of
Lili Wu, Ying Feng, Zhijun Wu, Hui Xu, Cheng Zhang, Jie Ning, Rong Wang, Jianqiong Chen, Minmin Xie, Yi Zhang, Lijia Bu, Jiqing Hao, Tai Ma   +12 more
doaj   +1 more source